Keystone Pharmaceuticals-B (02616) announcedluckytimeYang Jianxin, CEO, President of R & D and Executive Director of the company, purchased a total of 334 yuan on the open market with his own funds during approximately six months prior to the date of this announcement.luckytime.50,000 shares. Since Yang Jianxin became CEO in August 2022, he has purchased a total of 752 yuanluckytime.950,000 shares, with a buying price range of HKD 0.82 to HKD 4.60. After making the share purchase, Yang Jianxin held an aggregate amount equivalent to the company's share purchase price on the date of this announcementluckytimeShares of approximately 4.97% of the total issued share capital of the company.
Yang Jianxin expressed to the company that he was full of confidence in the company's future prospects, and that increasing his shareholding in the company represented his belief in the company's ability to maintain stable operations while achieving rapid growth in a complex and ever-changing market environment, as well as for the company's growth and development. Unremittingly support. Yang Jianxin does not rule out the possibility of further increasing his shareholding in the company in due course.